Is Spinal Decompression Being Misunderstood? New Review Challenges How the Medical Community Interprets the Evidence

Dr. Anuj Gupta argues that advances in biomechanics, delivery and oscillation deserve evaluation on their own evidence—not old traction assumptions.

ATLANTA, GA, UNITED STATES, October 14, 2026 /EINPresswire.com/ — Spinal decompression, rooted in traction, is a non-surgical treatment designed to reduce pressure on spinal discs and surrounding structures through controlled mechanical forces and movement. For decades, traction has occupied an uncertain place in the treatment of chronic low back pain. Early forms produced inconsistent results, and the skepticism that followed became deeply embedded in both clinical thinking and the medical literature.

But has that history also shaped how newer spinal decompression technologies are being judged?

A peer-reviewed review by orthopedic spine surgeon Dr. Anuj Gupta, published in Cureus, examines the evolution of traction-based treatment into controlled non-surgical spinal decompression, including IDD Therapy^®.

Rather than asking simply whether “traction works,” Gupta’s review examines whether newer technologies, with controlled decompressive forces, targeted positioning and oscillatory movement, deserve to be evaluated differently from older forms of traction.

His review suggests they do.

When an Old Treatment Name Follows a New Technology

Traditional traction generally relies on longitudinal pulling forces intended to create separation between spinal structures. Modern spinal decompression technologies may incorporate controlled force progression, specific positioning, distraction and relaxation cycles, and oscillatory movement.

Gupta describes spinal decompression as an evolution of traction rather than an entirely separate concept. However, he cautions against applying conclusions from older traction studies across different technologies, protocols and patient populations.

That distinction can be important because medical conclusions about “traction” may not apply equally to every technology or treatment protocol using a similar terminology.

The issue is especially relevant for patients with disc-related back or neck pain, where treatment goals may include reducing mechanical stress and addressing factors associated with disc pathology.

An Older Cited Study Illustrates the Problem

One example highlighted in Gupta’s review is a 2009 randomized clinical trial often cited in discussions of IDD Therapy.

The trial compared patients receiving the standard IDD Therapy protocol with patients receiving a lower-force protocol described as a sham condition.

But there was an important detail: both groups were treated on the same decompression system and both received decompressive forces.

The difference was primarily the amount of force.

Patients in the full-treatment group progressed to approximately half body weight plus 10 pounds, while the sham group received 10 pounds.

Both groups experienced statistically significant improvements in low-back pain, leg pain, functional outcomes and quality of life, although the study did not find a statistically significant difference between groups.

Gupta argues that another interpretation deserves consideration.

“That randomized trial is not ‘treatment’ versus ‘placebo,’” said Gupta.

His review questions how the study compared higher-intensity treatment with a lower-intensity intervention that still involved mechanical decompressive force.

Why the “Sham” Question Matters

The distinction reaches beyond semantics.

Mechanical loading can affect the behavior of spinal tissues. Gupta discusses potential effects involving pressure gradients, fluid exchange and biological responses.

In other words, a lower dose is not necessarily the same thing as no dose.

That makes the 2009 trial an example of a broader challenge in spinal-decompression research: how to design a control condition for a physical treatment when the control itself may produce a mechanical effect.

Modern Decompression Is More Than a Pulling Force

Gupta’s review also examines characteristics intended to distinguish modern decompression from traditional traction.

IDD Therapy delivered on the ACCU-SPINA^® System incorporates controlled distraction/relaxation cycles, level-specific positioning and sinusoidal oscillation.

The review discusses potential biomechanical effects involving disc pressure, fluid exchange and paraspinal muscle activity. Protective muscle contraction or guarding may counteract distraction, making the way decompression is delivered clinically relevant.

Dose Matters, Too

Another problem identified in the literature is treatment dosage.

Not every study labeled as an evaluation of spinal decompression has used the same number of sessions, force levels or treatment protocols.

“Underdosing may limit therapeutic effect and thus affect outcomes,” Gupta notes, pointing to studies that used fewer sessions than recommended and reported suboptimal outcomes.

That suggests researchers and clinicians may need to ask more specific questions:

• What technology was used?
• How was the force delivered?
• What treatment dose and number of sessions were provided?
• Which patients were selected?
• What condition was actually being treated?

Those distinctions are routine considerations in pharmaceutical research, where the drug, dose, duration and patient population are clearly defined.

Not a Treatment for Every Back Pain Patient

The review does not suggest spinal decompression is appropriate for every patient with back pain.

Gupta emphasizes that back pain can arise from numerous structures and causes, and that patient selection is important.

“I believe IDD therapy has a role in disc-related back pain, specifically in selected patients,” Gupta states in the review.

His published conclusion similarly characterizes IDD Therapy as an evolution of traction involving controlled decompressive forces and calls for larger, long-term studies.

A Case for Re-Examining the Evidence

The larger question raised by Gupta’s review is not whether decades of traction research should be disregarded.

It is whether newer technology should continue to inherit the scientific reputation of older forms of traction simply because they share a historical connection.

Medicine routinely revisits treatments as technology advances. For spinal decompression, Gupta argues that meaningful evaluation requires attention to the actual technology, biomechanics, treatment protocol and patient population.

The controversial “sham” trial is one illustration of why those distinctions matter.

For researchers, clinicians and patients evaluating these options, the broader question may be:

“Which form of decompression, delivered how, and for which patient?”

IDD Therapy^® is delivered on the ACCU-SPINA^® System, manufactured by North American Medical Corporation.

About Dr. Anuj Gupta

Dr. Anuj Gupta is an orthopedic spine surgeon whose clinical and academic work focuses on spinal disorders. His paper, “Evolving Spinal Treatment Modalities: A Review of the Literature on Non-surgical Interferential Differential Dynamics (IDD) Therapy,” was published in Cureus in May 2024.

About North American Medical Corporation

North American Medical, based in Marietta, Georgia, develops and manufactures medical technologies for non-surgical spine and musculoskeletal care, including the ACCU-SPINA^® System.

Media Contact

Gidgette Rubin
Senior Vice President
Rubin@NAMcorporation.com
770-541-0012 ext. 5333
www.NAMcorporation.com

Gidgette B Rubin
North American Medical Corporation
+1 770-541-0012

Media gallery